Carboplatin + Palifosfamide-tris + Etoposide + Carboplatin
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-Stage Small Cell Lung Cancer
Conditions
Extensive-Stage Small Cell Lung Cancer
Trial Timeline
May 1, 2012 → Jun 1, 2015
NCT ID
NCT01555710About Carboplatin + Palifosfamide-tris + Etoposide + Carboplatin
Carboplatin + Palifosfamide-tris + Etoposide + Carboplatin is a phase 3 stage product being developed by Alaunos Therapeutics for Extensive-Stage Small Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT01555710. Target conditions include Extensive-Stage Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01555710 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Extensive-Stage Small Cell Lung Cancer